Recent advances in chemistry and biology of gamboge

Zhongguo Zhongyao Zazhi

Volumn 38, Issue 1, 2013, Pages 19-25

  Yang, Jing ^a,e   Ding, Li ^a   Liu, Wen Yuan ^a   Feng, Feng ^a,b   Guo, Qing Long ^b,c   You, Qi Dong ^b,c,d  

^a Department of Pharmaceutical Analysis ^*  (China)

^b Jiangsu Key Laboratory of Carcinogenesis and Intervention   (China)

^c China Pharmaceutical University   (China)

^d CHINA PHARMACEUTICAL UNIVERSITY   (China)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

, unsaturated ketone; Antitumor; Gamboge; Gambogic acid; Metabolism; Michael addition reaction; Sulfonation; Target protein

Indexed keywords

ANTINEOPLASTIC AGENT; GAMBOGE; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CHEMISTRY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; GARCINIA; HUMANS; PLANT EXTRACTS; RESINS, PLANT;

EID: 84877074105     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20130105     Document Type: Review

References (77)

1. Han Q B, Xu H X. Caged Garcinia xanthones: development since 1937 [J]. Curr Med Chem, 2009, 16 (28): 3775.
2. 1982 (3): 1.
3. 1981, 8 (4): 230.
4. 1986, 13 (2): 111.
5. 1986 (3): 46.
6. 1986 (1): 31.
7. 2003, 10 (2): 216.
8. Guo Q L, You Q D, Wu Z Q, et al. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice [J]. Acta Pharmacol Sin, 2004, 25 (6): 769.
9. Han Q B, Wang Y L, Yang L, et al. Cytotoxic polyprenylated xanthones from the resin of Garcinia hanburyi [J]. Chem Pharm Bull, 2006, 54 (2): 265.
10. Asano J, Chiba K, Tada M, et al. Cytotoxic xanthones from Garcinia hanburyi[J]. Phytochemistry, 1996, 41(3): 815.
11. 1980 (2): 1.
12. 2008, 66 (22): 2513.
13. Tao S J, Guan S H, Wang W, et al. Cytotoxic polyprenylated xanthones from the resin of Garcinia hanburyi [J]. J Nat Prod, 2009, 72(1): 117.
14. 2008, 43(8): 838.
15. Zhou Y, Liu X, Yang J, et al. Analysis of caged xanthones from the resin of Garcinia hanburyi using ultra-performance liquid chromatography/electrospray ionization quadrupole time-of-flight tandem mass spectrometry [J]. Anal Chim Acta, 2008, 629(1/2): 104.
16. Yang J, Ding L, Hu L, et al. Rapid characterization of caged xanthones in the resin of Garcinia hanburyi using multiple mass spectrometric scanning modes: the importance of biosynthetic knowledge based prediction [J]. J Pharm Biomed Anal, 2012, 60(4): 71.
17. Han Q, Yang L, Liu Y, et al. Gambogic acid and epigambogic acid, C-2 epimers with novel anticancer effects from Garcinia hanburyi[J]. Planta Med, 2006, 72(3): 281.
18. Feng F, Liu W Y, Chen Y S, et al. Five novel prenylated xanthones from Resina Garciniae [J]. J Asian Nat Prod Res, 2007, 9(6/8): 735.
19. Lin L J, Lin L Z, Pezzuto J M, et al. Isogambogic acid and isomorellinol from Garcinia hanburyi [J]. Magn Reson Chem, 1993, 31: 340.
20. Han Q B, Song J Z, Qiao C F, et al. Preparative separation of gambogic acid and its C-2 epimer using recycling high-speed counter-current chromatography [J]. J Chromatogr A, 2006, 1127(1/2): 298.
21. Han Q B, Yang L, Wang Y L, et al. A pair of novel cytotoxic polyprenylated xanthone epimers from gamboges [J]. Chem Biodivers, 2006, 3(1): 101.
22. Qiang L, Yang Y, You Q D, et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study [J]. Biochem Pharmacol, 2008, 75(5): 1083.
23. Lu N, Yang Y, You Q D, et al. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1 [J]. Cancer Lett, 2007, 258(1): 80.
24. Chantarasriwong O, Batova A, Chavasiri W, et al. Chemistry and biology of the caged Garcinia xanthones [J]. Chemistry, 2010, 16(33): 9944.
25. 2011, 35(8): 337.
26. 2006, 4(3): 2210.
27. Wang X, Lu N, Yang Q, et al. Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity [J]. Eur J Med Chem, 2011, 46(4): 1280.
28. Wu Z Q, Guo Q L, You Q D, et al. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells [J]. Biol Pharm Bull, 2004, 27(11): 1769.
29. Zhao L, Guo Q L, You Q D, et al. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells [J]. Biol Pharm Bull, 2004, 27(7): 998.
30. Liu W, Guo Q L, You Q D, et al. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823 [J]. World J Gastroenterol, 2005, 11(24): 3655.
31. Guo Q L, Lin S S, You Q D, et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells [J]. Life Sci, 2006, 78(11): 1238.
32. Yu J, Guo Q L, You Q D, et al. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells [J]. Cancer Chemother Pharmacol, 2006, 58(4): 434.
33. Yu J, Guo Q L, You Q D, et al. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells [J]. Carcinogenesis, 2007, 28(3): 632.
34. Chen J, Gu H Y, Lu N, et al. Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells [J]. Life Sci, 2008, 83 (3/4): 103.
35. Gu H, Wang X, Rao S, et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells [J]. Mol Cancer Ther, 2008, 7 (10): 3298.
36. Gu H, You Q, Liu W, et al. Gambogic acid induced tumor cell apoptosis by T-lymphocyte activation in H22 transplanted mice [J]. Int Immunopharmacol, 2008, 8(11): 1493.
37. Qi Q, Gu H, Yang Y, et al. Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis [J]. J Mol Med (Berl), 2008, 86(12): 1367.
38. Qi Q, Lu N, Wang X T, et al. Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells [J]. Biochem Cell Biol, 2008, 86(5): 386.
39. Zhao J, Qi Q, Yang Y, et al. Inhibition of alpha (4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid [J]. Eur J Pharmacol, 2008, 589(1/3): 127.
40. Zhao Q, Yang Y, Yu J, et al. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells [J]. Cancer Lett, 2008, 262(2): 223.
41. Gu H, Rao S, Zhao J, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells [J]. J Cancer Res Clin Oncol, 2009, 135(12): 1777.
42. Nie F, Zhang X, Qi Q, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells [J]. Toxicology, 2009, 260(1/3): 60.
43. Rong J J, Hu R, Qi Q, et al. Gambogic acid down-regulates MDM2 oncogene and induces p21 (Waf1/CIP1) expression independent of p53 [J]. Cancer Lett, 2009, 284(1): 102.
44. Rong J J, Hu R, Song X M, et al. Gambogic acid triggers DNA damage signaling that induces p53/p21 (Waf1/CIP1) activation through the ATR-Chk1 pathway [J]. Cancer Lett, 2010, 296 (1): 55.
45. Wang J, Zhao Q, Qi Q, et al. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP [J]. J Cell Biochem, 2011, 112(2): 509.
46. Li C, Lu N, Qi Q, et al. Gambogic acid inhibits tumor cell adhesion by suppressing integrin beta1 and membrane lipid rafts-associated integrin signaling pathway [J]. Biochem Pharmacol, 2011, 82(12): 1873.
47. Qin Y, Meng L, Hu C, et al. Gambogic acid inhibits the catalytic activity of human topoisomerase II alpha by binding to its AT-Pase domain [J]. Mol Cancer Ther, 2007, 6(9): 2429.
48. Kasibhatla S, Jessen K A, Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid [J]. Proc Natl Acad Sci USA, 2005, 102 (34): 12095.
49. Zhai D, Jin C, Shiau C W, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins [J]. Mol Cancer Ther, 2008, 7(6): 1639.
50. Pandey M K, Sung B, Ahn K S, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway [J]. Blood, 2007, 110(10): 3517.
51. 2007, 16 (1): 79.
52. Yang Y, Yang L, You Q D, et al. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes [J]. Cancer Lett, 2007, 256(2): 259.
53. Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation [J]. Cell, 2011, 144(5): 646.
54. Lu L, Tang D, Wang L, et al. Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappaB signaling pathways [J]. Acta Pharmacol Sin, 2012, 33(4):531.
55. Yi T, Yi Z, Cho S G, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling [J]. Cancer Res, 2008, 68 (6): 1843.
56. 1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells [J]. Toxicology, 2009, 262(2): 98.
57. 1 cell cycle arrest and cell migration inhibition via suppressing PDGF receptor beta tyrosine phosphorylation and Rac1 activity in rat aortic smooth muscle cells [J]. J Atheroscler Thromb, 2010, 17 (9): 901.
58. Zhao W, Zhou S F, Zhang Z P, et al. Gambogic acid inhibits the growth of osteosarcoma cells in vitro by inducing apoptosis and cell cycle arrest [J]. Oncol Rep, 2011, 25(2):1289.
59. Palempalli U D, Gandhi U, Kalantari P, et al. Gambogic acid covalently modifies I kappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages [J]. Biochem J, 2009, 419(2): 401.
60. Panthong A, Norkaew P, Kanjanapothi D, et al. Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from Garcinia hanburyi Hook f [J]. J Ethnopharmacol, 2007, 111(2): 335.
61. Zhang L, Yi Y, Chen J, et al. Gambogic acid inhibits Hsp90 and deregulates TNF-alpha/NF-kappaB in HeLa cells [J]. Biochem Biophys Res Commun, 2010, 403(3/4): 282.
62. Yang J, Ding L, Hu L, et al. Comparison of electron capture-atmospheric pressure chemical ionization and electrospray ionization for the analysis of gambogic acid and its main circulating metabolite in dog plasma [J]. Eur J Mass Spectrom, 2010, 16(5): 605.
63. Lopachin R M, Gavin T, Decaprio A, et al. Application of the hard and soft, acids and bases (HSAB) theory to toxicant-target interactions [J]. Chem Res Toxicol, 2012, 25(2): 239.
64. Weerapana E, Wang C, Simon G M, et al. Quantitative reactivity profiling predicts functional cysteines in proteomes [J]. Nature, 2010, 468(7325): 790.
65. Yang J, Li C, Ding L, et al. Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain [J]. J Nat Prod, 2012, 75(6): 1108.
66. Schmitt E K, Moore C M, Krastel P, et al. Natural products as catalysts for innovation: a pharmaceutical industry perspective [J]. Curr Opin Chem Biol, 2011, 15(4): 497.
67. Bottcher T, Pitscheider M, Sieber S A. Natural products and their biological targets: proteomic and metabolomic labeling strategies [J]. Angew Chem Int Ed Engl, 2010, 49(15): 2680.
68. Codreanu S G, Zhang B, Sobecki S M, et al. Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal [J]. Mol Cell Proteomics, 2009, 8(4): 670.
69. Jacobs A T, Marnett L J. Systems analysis of protein modification and cellular responses induced by electrophile stress [J]. Acc Chem Res, 2010, 43(5): 673.
70. 1989(3): 9.
71. 2005, 36(4): 338.
72. Hao K, Liu X Q, Wang G J, et al. Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats [J]. Eur J Drug Metab Pharmacokinet, 2007, 32(2): 63.
73. Hao K, Zhao X P, Liu X Q, et al. Determination of gambogic acid in dog plasma by high-performance liquid chromatography for a pharmacokinetic study [J]. Biomed Chromatogr, 2007, 21 (3): 279.
74. Yang J, Ding L, Hu L, et al. Comparison of electron capture-atmospheric pressure chemical ionization and electrospray ionization for the analysis of gambogic acid and its main circulating metabolite in dog plasma [J]. Eur J Mass Spectrom, 2010, 16(5): 605.
75. Feng F, Liu W, Wang Y, et al. Structure elucidation of metabolites of gambogic acid in vivo in rat bile by high-performance liquid chromatography-mass spectrometry and high-performance liquid chromatography-nuclear magnetic resonance [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 860(2): 218.
76. Zhang L, You Q, Liang Y, et al. Identification of gambogic acid metabolites in rat bile by liquid chromatography-tandem mass spectrometry-ion trap-time-of-flight [J]. Chin J Nat Med, 2009, 7(5): 376.
77. Yang J, Ding L, Hu L, et al. Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition [J]. Drug Metab Dispos, 2011, 39(4): 617.